← Back to Clinical Trials
RecruitingNCT07022041

Sepsis and Hospital Mortality

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionSepsis
SponsorUniversity of Calabria
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment100
SexALL
Min Age18 Years
Max AgeN/A
Start Date2025-07-15
Completion2026-07-15
Interventions
conductivity and dieletric constant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Sepsis is one of the leading causes of hospital mortality, with a rate of approximately 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards. Currently, diagnostic criteria such as the Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack sufficient specificity and accuracy. No established parameters are available for early and timely diagnosis. This study aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes previously validated for non-invasive glucose monitoring. The acquired data will be analyzed using the Anritsu VectorStar VNA to identify innovative and reliable parameters associated with the presence of severe infections.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Cardiology patients without documented infection (Control Group) * Patients with sepsis * Patients with nosocomial infection * Patients with myocarditis, endocarditis, or pericarditis * Ability to provide written informed consent Exclusion Criteria: * Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure * Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants * Patients with cancer * Patients with diseases involving the immune system (e.g., lymphomas, leukemias) * Patients with congenital or acquired immunodeficiencies (e.g., HIV) * Patients who are unable to read and sign the informed consent form

Related Trials